<DOC>
	<DOCNO>NCT00409981</DOCNO>
	<brief_summary>The PACCOCATH ISR II study randomize , double-blinded German multicenter trial efficacy tolerance paclitaxel coat balloon catheter coronary in-stent restenosis .</brief_summary>
	<brief_title>Treatment in-Stent Restenosis Paclitaxel Coated PTCA Balloons ( PACCOCATH – ISR II )</brief_title>
	<detailed_description>Background : Drug-eluting stent show promising anti-restenotic effect clinical trial . It may preferable , however , avoid stent-in-stent approach treat in-stent restenosis ( ISR ) . In prior animal trial , demonstrate highly significant reduction neointimal formation drug-eluting balloon catheter ( DEB ) . The aim PACCOCATH ISR study investigate novel DEB treatment ISR . Methods result : The PACCOCATH ISR study randomize , double-blind German multicenter trial efficacy tolerance DEB coronary ISR . Patients randomize rePTCA ISR either use coated PTCA balloon ( 3 µg paclitaxel/mm² balloon surface ) non-coated balloon type ( n=56 patient ) . Balloon inflation time 60 second case . Major inclusion criterion ISR coronary artery diameter stenosis least 70 % , &lt; 30 mm length , vessel diameter 2.5 3.5 mm . The primary endpoint late lumen loss 6 month ( independent angiographic core lab ) . Secondary endpoint binary restenosis rate major adverse cardiac event .</detailed_description>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Age &gt; 18 year Clinical evidence stable unstable angina positive functional study Single , restenotic lesion stented coronary artery ( allow multiple lesion target lesion amenable percutaneous intervention , i.e . ‘ stag ’ procedure involve nontarget lesion ) Diameter stenosis &gt; 70 % ( visual estimate ) Stented segment length &lt; 30 mm Vessel diameter = &gt; 2.5 mm Female patient enter study postmenopausal least two year undergone hysterectomy sterilization Signed patient inform consent form Patients treat physician agree patient return require post procedure followup assessment define clinical protocol Left ventricular ejection fraction &lt; 30 % Target lesion/vessel follow characteristic : Clear angiographic calcification target lesion great mild calcification proximal vessel ( minimally radiopaque density discrete nonlinear ) . Visible thrombus proximal lesion . Known hypersensitivity contraindication aspirin , heparin , clopidogrel , abciximab , paclitaxel , sensitivity contrast medium adequately premedicated . Other medical illness ( i.e . cancer , liver disease congestive heart failure ) may require cytostatic radiation therapy cause subject noncompliant protocol , confound data interpretation associate limited lifeexpectancy ( i.e. , less two year ) . Severe chronic renal insufficiency . Significant gastrointestinal ( GI ) bleed within past six month . History bleed diathesis coagulopathy refuse blood transfusion . Extensive peripheral vascular disease precludes safe 6 French sheath insertion and/or require additional antiplatelet and/or anticoagulation treatment . Participating another device drug study within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>stent restenosis</keyword>
	<keyword>paclitaxel coat balloon catheter</keyword>
	<keyword>paccocath</keyword>
	<keyword>drug elute balloon</keyword>
</DOC>